What is the share price of 3B Blackbio DX Ltd (3BBLACKBIO) today?
The share price of 3BBLACKBIO as on 27th February 2026 is ₹1351.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on 3B Blackbio DX Ltd (3BBLACKBIO) share?
The past returns of 3B Blackbio DX Ltd (3BBLACKBIO) share are- Past 1 week: -16.40%
- Past 1 month: -17.74%
- Past 3 months: 4.11%
- Past 6 months: -6.91%
- Past 1 year: -22.75%
- Past 3 years: 231.17%
- Past 5 years: 371.97%
What are the peers or stocks similar to 3B Blackbio DX Ltd (3BBLACKBIO)?
The peers or stocks similar to 3B Blackbio DX Ltd (3BBLACKBIO) include:What is the dividend yield % of 3B Blackbio DX Ltd (3BBLACKBIO) share?
The current dividend yield of 3B Blackbio DX Ltd (3BBLACKBIO) is 0.30.What is the market cap of 3B Blackbio DX Ltd (3BBLACKBIO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of 3B Blackbio DX Ltd (3BBLACKBIO) is ₹1159.95 Cr as of 27th February 2026.What is the 52 week high and low of 3B Blackbio DX Ltd (3BBLACKBIO) share?
The 52-week high of 3B Blackbio DX Ltd (3BBLACKBIO) is ₹2019.90 and the 52-week low is ₹1151.What is the PE and PB ratio of 3B Blackbio DX Ltd (3BBLACKBIO) stock?
The P/E (price-to-earnings) ratio of 3B Blackbio DX Ltd (3BBLACKBIO) is 24.32. The P/B (price-to-book) ratio is 4.28.Which sector does 3B Blackbio DX Ltd (3BBLACKBIO) belong to?
3B Blackbio DX Ltd (3BBLACKBIO) belongs to the Health Care sector & Biotechnology sub-sector.How to buy 3B Blackbio DX Ltd (3BBLACKBIO) shares?
You can directly buy 3B Blackbio DX Ltd (3BBLACKBIO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
3B Blackbio DX Ltd
3BBLACKBIO Share Price
BSE₹1,351.507.36% (-107.30)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
3BBLACKBIO Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
3BBLACKBIO Performance & Key Metrics
3BBLACKBIO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 20.20 | 4.28 | 0.30% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.86 | 5.82 | 0.58% |
3BBLACKBIO Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
3BBLACKBIO Company Profile
3B Blackbio DX Ltd specializes in PCR-based molecular diagnostic kits, offering a range of products for oncology, infectious diseases, and human genetics, serving diagnostics labs across India.
BIOCON
PE Ratio
62.29
62.29
1Y Return
25.00%
25.00%
Buy Reco %
86.67
86.67
ANTHEM
PE Ratio
87.29
87.29
1Y Return
3.98%
3.98%
Buy Reco %
100.00
100.00
SAILIFE
PE Ratio
124.26
124.26
1Y Return
42.53%
42.53%
Buy Reco %
100.00
100.00
ACUTAAS
PE Ratio
111.36
111.36
1Y Return
94.49%
94.49%
Buy Reco %
100.00
100.00
ONESOURCE
PE Ratio
-859.53
-859.53
1Y Return
4.92%
4.92%
Buy Reco %
100.00
100.00
3BBLACKBIO Sentiment Analysis
3BBLACKBIO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
3BBLACKBIO Stock Summary · February 2026
In Q3 FY26, the company demonstrated robust revenue growth, reaching INR 99.06 crores, bolstered by a strategic acquisition and strong brand loyalty, despite facing challenges from increased competition and market saturation. With a focus on developing innovative diagnostic products, particularly in infectious diseases and oncology, the company is poised to capture significant market potential, especially in the molecular diagnostics sector, estimated at INR 400 to 500 crores. However, navigating regulatory approvals, particularly for US FDA and European IVDR certifications, remains a critical hurdle that could impact future growth. While domestic growth is limited, promising export opportunities are anticipated, with a cautious yet optimistic outlook for revenue stability and profitability in the coming year.
3BBLACKBIO Stock Growth Drivers
3BBLACKBIO Stock Growth Drivers
7Significant Revenue Growth
The company reported substantial financial growth, achieving revenues of INR 99.06 crores for the nine
Positive Market Response and Customer Satisfaction
The company has received positive responses from distributors and customers, particularly following participation in Medlab,
3BBLACKBIO Stock Challenges
3BBLACKBIO Stock Challenges
4Negative Financial Performance
The company is currently facing significant financial challenges, including an expected negative EBITDA for the
Market Competition and Saturation
The company is experiencing intense competition in the molecular diagnostics market, leading to market saturation
3BBLACKBIO Forecast
3BBLACKBIO Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
3BBLACKBIO
3BBLACKBIO
Income
Balance Sheet
Cash Flow
Quarterly Normal View
3BBLACKBIO Income Statement
3BBLACKBIO Income Statement
Quarterly Normal View
| Quarter | sep 2023 | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 21.93 | 20.30 | 27.19 | 23.13 | 32.58 | 28.41 | 27.44 | 26.55 | 39.41 | 55.93 | ||||||||||
Operating & Other expenses | 11.39 | 8.79 | 13.12 | 8.49 | 12.97 | 10.32 | 14.57 | 10.40 | 19.17 | 28.63 | ||||||||||
EBITDA | 10.54 | 11.51 | 14.07 | 14.64 | 19.61 | 18.09 | 12.87 | 16.15 | 20.24 | 27.30 | ||||||||||
| Depreciation/Amortization | 0.24 | 0.32 | 0.30 | 0.27 | 0.27 | 0.27 | 0.28 | 0.28 | 0.58 | 0.38 | ||||||||||
| PBIT | 10.30 | 11.19 | 13.77 | 14.37 | 19.34 | 17.82 | 12.59 | 15.87 | 19.66 | 26.92 | ||||||||||
| Interest & Other Items | 0.04 | 0.03 | 0.04 | 0.01 | 0.03 | 0.02 | 0.04 | 0.01 | 0.04 | 0.09 | ||||||||||
| PBT | 10.26 | 11.16 | 13.73 | 14.36 | 19.31 | 17.80 | 12.55 | 15.86 | 19.62 | 26.83 | ||||||||||
| Taxes & Other Items | 2.40 | 2.43 | 4.86 | 3.23 | 4.66 | 4.39 | 4.14 | 3.28 | 4.91 | 5.11 | ||||||||||
| Net Income | 7.86 | 8.73 | 8.87 | 11.13 | 14.65 | 13.41 | 8.41 | 12.58 | 14.71 | 21.72 | ||||||||||
| EPS | 8.86 | 9.94 | 10.26 | 13.19 | 17.35 | 15.75 | 9.38 | 14.76 | 17.55 | 26.19 |
3BBLACKBIO Company Updates
3BBLACKBIO Stock Peers
3BBLACKBIO Past Performance & Peer Comparison
3BBLACKBIO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| 3B Blackbio DX Ltd | 24.32 | 4.28 | 0.30% |
| Biocon Ltd | 62.29 | 2.28 | 0.10% |
| Anthem Biosciences Ltd | 87.29 | 16.35 | — |
| Sai Life Sciences Ltd | 124.26 | 9.93 | — |
3BBLACKBIO Stock Price Comparison
Compare 3BBLACKBIO with any stock or ETFCompare 3BBLACKBIO with any stock or ETF
3BBLACKBIO
3BBLACKBIO Holdings
3BBLACKBIO Shareholdings
3BBLACKBIO Promoter Holdings Trend
3BBLACKBIO Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
3BBLACKBIO Institutional Holdings Trend
3BBLACKBIO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
3BBLACKBIO Shareholding Pattern
3BBLACKBIO Shareholding Pattern
3BBLACKBIO Shareholding History
3BBLACKBIO Shareholding History
Foreign Institutions
Mutual Funds Invested in 3BBLACKBIO
Mutual Funds Invested in 3BBLACKBIO
No mutual funds holding trends are available
Top 1 Mutual Funds holding 3B Blackbio DX Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0008% | Percentage of the fund’s portfolio invested in the stock 0.06% | Change in the portfolio weight of the stock over the last 3 months 0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 88/123 (+8) |
Compare 3-month MF holding change on Screener
smallcases containing 3BBLACKBIO stock
smallcases containing 3BBLACKBIO stock
Looks like this stock is not in any smallcase yet.
3BBLACKBIO Events
3BBLACKBIO Events
3BBLACKBIO Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
3BBLACKBIO has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.27%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.74 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
3BBLACKBIO Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
3BBLACKBIO has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.27%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.74 every year
3BBLACKBIO Upcoming Dividends
3BBLACKBIO Upcoming Dividends
No upcoming dividends are available
3BBLACKBIO Past Dividends
3BBLACKBIO Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2025
Final
Final | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Sep 19, 2025
Cash Dividend
Ex DateEx DateSep 17, 2024
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 17, 2024
Cash Dividend
Ex DateEx DateSep 15, 2023
Final
Final | Div/Share: ₹2.50
Dividend/Share
₹2.50
Ex DateEx Date
Sep 15, 2023
Cash Dividend
Ex DateEx DateSep 14, 2022
Final
Final | Div/Share: ₹2.50
Dividend/Share
₹2.50
Ex DateEx Date
Sep 14, 2022
Cash Dividend
Ex DateEx DateSep 14, 2021
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 14, 2021
3BBLACKBIO Stock News & Opinions
3BBLACKBIO Stock News & Opinions
Articles & Videos
Earnings
3B Blackbio DX consolidated net profit rises 62.16% in the December 2025 quarter
Net profit of 3B Blackbio DX rose 62.16% to Rs 21.73 crore in the quarter ended December 2025 as against Rs 13.40 crore during the previous quarter ended December 2024. Sales rose 98.31% to Rs 50.35 crore in the quarter ended December 2025 as against Rs 25.39 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales50.3525.39 98 OPM %43.1259.39 - PBDT27.2218.06 51 PBT26.8417.80 51 NP21.7313.40 62 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
3B Blackbio DX to conduct board meeting
3B Blackbio DX will hold a meeting of the Board of Directors of the Company on 6 February 2026.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Earnings
3B Blackbio DX consolidated net profit rises 0.41% in the September 2025 quarter
Net profit of 3B Blackbio DX rose 0.41% to Rs 14.71 crore in the quarter ended September 2025 as against Rs 14.65 crore during the previous quarter ended September 2024. Sales rose 16.30% to Rs 33.90 crore in the quarter ended September 2025 as against Rs 29.15 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales33.9029.15 16 OPM %43.4555.47 - PBDT20.2019.58 3 PBT19.6219.31 2 NP14.7114.65 0 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
3B Blackbio DX to table results
3B Blackbio DX will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
3B Blackbio DX schedules AGM
3B Blackbio DX announced that the Annual General Meeting(AGM) of the company will be held on 26 September 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
3D Blackbio DX to convene board meeting
3D Blackbio DX will hold a meeting of the Board of Directors of the Company on 14 August 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
3B BlackBio Dx announces demise of director
3B BlackBio Dx announced the sad demise of Rajesh Dubey (DIN: 10738590), Independent Director of the company on 13 July 2025.Powered by Capital Market - Live
7 months agoCapital Market - Live
Spotlight
3B Blackbio DX Ltd leads losers in 'B' group
Denta Water & Infra Solutions Ltd, Delta Manufacturing Ltd, Alpa Laboratories Ltd and Ashoka Metcast Ltd are among the other losers in the BSE's 'B' group today, 29 May 2025.3B Blackbio DX Ltd crashed 15.76% to Rs 1593.95 at 14:31 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 64484 shares were traded on the counter so far as against the average daily volumes of 5986 shares in the past one month.Denta Water & Infra Solutions Ltd tumbled 10.06% to Rs 282.1. The stock was the second biggest loser in 'B' group.On the BSE, 2.24 lakh shares were traded on the counter so far as against the average daily volumes of 31928 shares in the past one month.Delta Manufacturing Ltd lost 10.00% to Rs 88.42. The stock was the third biggest loser in 'B' group.On the BSE, 7938 shares were traded on the counter so far as against the average daily volumes of 6462 shares in the past one month.Alpa Laboratories Ltd plummeted 9.05% to Rs 105.05. The stock was the fourth biggest loser in 'B' group.On the BSE, 14557 shares were traded on the counter so far as against the average daily volumes of 4563 shares in the past one month.Ashoka Metcast Ltd slipped 8.55% to Rs 17.75. The stock was the fifth biggest loser in 'B' group.On the BSE, 1.08 lakh shares were traded on the counter so far as against the average daily volumes of 8313 shares in the past one month.Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Board of 3D Blackbio DX recommends final dividend
3D Blackbio DX announced that the Board of Directors of the Company at its meeting held on 28 May 2025, inter alia, have recommended the final dividend of Rs 4 per equity Share (i.e. 40%) , subject to the approval of the shareholders.Powered by Capital Market - Live
9 months agoCapital Market - Live
Earnings
3B Blackbio DX consolidated net profit declines 5.30% in the March 2025 quarter
Net profit of 3B Blackbio DX declined 5.30% to Rs 8.40 crore in the quarter ended March 2025 as against Rs 8.87 crore during the previous quarter ended March 2024. Sales declined 2.17% to Rs 22.50 crore in the quarter ended March 2025 as against Rs 23.00 crore during the previous quarter ended March 2024. For the full year,net profit rose 45.59% to Rs 47.65 crore in the year ended March 2025 as against Rs 32.73 crore during the previous year ended March 2024. Sales rose 30.15% to Rs 96.47 crore in the year ended March 2025 as against Rs 74.12 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales22.5023.00 -2 96.4774.12 30 OPM %35.2042.96 -51.9444.50 - PBDT12.8214.03 -9 65.0845.39 43 PBT12.5413.73 -9 64.0044.33 44 NP8.408.87 -5 47.6532.73 46 Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 29.63%, vs industry avg of 21.23%
Over the last 5 years, market share increased from 0.33% to 0.47%
Over the last 5 years, net income has grown at a yearly rate of 44.08%, vs industry avg of 23.38%